Lotte Biologics Completes Incheon Plant, Aiming for 1 Trillion Won in Annual Revenue

Lotte Biologics has completed its first plant at the Incheon Songdo Bio Campus and is set to aggressively target the global contract development and manufacturing organization (CDMO) market. By leveraging a 'dual site' strategy that combines its facilities in Syracuse, New York, and Songdo, the company plans to generate annual revenue of 1 trillion won (KRW) when both plants are fully operational. Notably, just before the completion, Lotte secured its first large-scale commercial production volume, which is expected to accelerate its growth despite competition from latecomers.

Lotte Biologics held a completion ceremony for its first plant at the Songdo Bio Campus on the morning of November 18. After entering the biotech sector four years ago, the company has established a large-scale production base in South Korea. The ceremony was attended by approximately 300 officials, including Shin Dong-bin, chairman of Lotte Group, Shin Yoo-yeol and Park James, co-CEOs of Lotte Biologics, and Park Chan-dae, the mayor of Incheon.

In his congratulatory speech, Chairman Shin stated, "I hope that the completion of the Songdo Bio Campus's first plant will serve as a significant turning point that enhances the competitiveness of the South Korean biotech industry beyond the growth of Lotte Group."

Shin Yoo-yeol, who was promoted to president of Lotte Holdings just two days prior, also attended. He remarked, "We have laid the foundation for Lotte Biologics to contribute to enhancing the large-scale production capacity of the South Korean biotech industry, beyond just completing the new production facility. We aim to be a CDMO partner that accompanies our clients in the long term, based on quality, technology, and trust that customers can feel."

The Songdo Plant, which began construction in March 2024, features a production facility with a capacity of 120,000 liters, equipped with eight stainless steel bioreactors of 15,000 liters each. The total floor area is approximately 100,000 square meters. It also includes a 3,000-liter bioreactor and small-scale cultivation equipment to meet the demand for high-value products. The facility employs a top-down method to create culture media on the top floor, utilizing gravity to transfer it to the production line below. The logistics warehouse, which has 6,030 storage spaces, uses robots for the inbound and outbound of raw materials and autonomous robots for specimen transport.

Jeong Woo-cheong, head of the EPC division at Lotte Biologics, explained that the Songdo Plant is designed to be five stories high, equivalent to a 14- to 15-story apartment building. He added, "By applying a top-down method that utilizes gravity, we have reduced cell damage and increased energy efficiency." He also noted that the plant is located about 30 minutes from Incheon International Airport, providing excellent accessibility for overseas clients.

The plant is currently in the final stages of preparation for commercial production, including equipment qualification and process validation. Full-scale production is set to begin next year, with production volumes already secured. On November 17, just one day before the completion, Lotte Biologics signed its first large-scale commercial production contract with a global pharmaceutical company for the Songdo Plant, alleviating initial operational rate burdens before the plant's completion.

Lotte Group has identified CDMO as a new growth engine and established Lotte Biologics in June 2022. In December of the same year, it acquired Bristol-Myers Squibb's Syracuse plant in New York for $160 million (approximately 208 billion won). The company aims to absorb the demand for global supply chain restructuring, including the U.S. Biodefense Act, by linking the Syracuse plant, which has strengths in clinical volumes and antibody-drug conjugates (ADCs), with the large-scale commercial production base at the Songdo Plant through its 'dual site' strategy.

Jeon Ji-won, head of the strategic planning division at Lotte Biologics, stated, "At maximum capacity, we can generate approximately 300 billion won (KRW) from the Syracuse plant and about 700 billion won (KRW) from the Songdo Plant, totaling 1 trillion won (KRW) in revenue. Our dual site strategy, which combines proven production capabilities in the U.S. with advanced infrastructure in Korea, will provide global clients with a variety of production options." He added, "Since our launch in 2022, we expect the cumulative order volume to reach up to $1.9 billion (approximately 2 trillion won) by the end of this year."

Lotte Biologics also plans to further increase its production capacity in Songdo. The company intends to build additional plants 2 and 3 in Songdo, expanding domestic production capacity to 360,000 liters. The timing of construction will be flexibly determined based on order conditions. The company anticipates that once all three plants are completed, it will create 37,000 jobs and generate a production inducement effect of 7.6 trillion won (KRW). With existing production facilities from Samsung Biologics and Celltrion already established in Songdo, the area has become a hub for leading domestic biotech companies. Jeon stated, "Songdo is a bio-specialized complex that surpasses Singapore and Boston in terms of single-city standards."





* This article has been translated by AI.